Africa Health Research Institute news release
The first results from the Mobile Men study, presented at AIDS 2026, show that long-acting injectable cabotegravir (CAB-LA) helped men who travel for work stay on HIV prevention for longer than oral PrEP. The study also found that same-day HIV testing and starting injectable PrEP was feasible. For those taking oral PrEP, the study found that event-based PrEP (alone or combined with daily) was preferred to daily-only dosing.
The study, conducted in Uganda and South Africa, explored the uptake, persistence (continuing to receive treatment on schedule) and preferences for long-acting injectable PrEP compared with oral PrEP among men whose work requires frequent travel. Researchers enrolled participants through mobile clinics at taxi ranks, construction sites, and truck stops in the Eastern Cape and KwaZulu-Natal in South Africa, and through referrals from fishing communities to a clinic in Masaka, Uganda.
Read the full news release here.
Source : Africa Health Research Institute
Related HIV and Co-Infections News
-
[AIDS 2026] MedPage Today: Long-acting lenacapavir still delivered effective HIV PrEP after a year
-
[AIDS 2026] Managed Healthcare Executive: Community-led chemsex harm reduction programs boost HIV retention in South Africa, other countries
-
Results of the CAPRISA 012c clinical trial of a combination of two bnAbs to prevent HIV infection in young women in southern Africa announced at AIDS 2026
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.